AMT-116 in Patients With Advanced Solid Tumors

Part of paid clinical trials in Denver, Colorado.

Sponsor
Multitude Therapeutics Inc.
Study ID
NCT05725291
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • AMT-116 — DRUG
    Administered intravenously

Study Details

This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-116, in Patients with Advanced Solid Tumors

Key Dates

Start date
Jul 25, 2023
Status verified
Aug 2025
Primary completion
Dec 30, 2026
Completion
Dec 30, 2026

Study Design

Enrollment
80 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: AMT-116 Dose Escalation

Primary Outcome Measure

Recommended Phase 2 Dose (RP2D) [ Time Frame: Up to 24 months ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Sarah Cannon Research InstituteDenverColorado80218
Perez Batista Cesar Augusto
Mary Crowley Cancer Research CentersDallasTexas75230
Orr Douglas

Find similar trials in Denver, CO

By research site
Sarah Cannon Research Institute· Denver, COMary Crowley Cancer Research Centers· Dallas, TX

Related Studies